The Inflammation Hypothesis and Its Potential Relevance to Statin Therapy

American Journal of Cardiology

Volumn 99, Issue 5, 2007, Pages 732-738

  Forrester, James S ^a   Libby, Peter ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DONEPEZIL; GADOLINIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE MODEL; DRUG DOSE TITRATION; DRUG EFFECT; FIBROSIS; HEART FAILURE; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

CHRONIC DISEASE; CYTOKINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION;

EID: 33847050858     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.09.125     Document Type: Review

References (58)

1. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
2. Forrester J.S., and Bick-Forrrester J. Persistence of inflammation is a cause of chronic progressive diseases. Med Hypotheses 65 (2005) 227-231
3. Forrester J.S. Prevention of plaque rupture: a new paradigm of therapy. Ann Intern Med 137 (2002) 823-833
4. Goldstein B.J. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 90 suppl (2002) 3G-10G
5. Meier J.J., Ritzel R.A., Maedler K., Gurlo T., and Butler P.C. Increased vulnerability of newly forming beta cells to cytokine-induced cell death. Diabetologia 49 (2006) 83-89
6. Lang C.H., Dobrescu C., and Bagby G.J. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130 (1992) 43-52
7. Koistinaho M., and Koistinaho J. Interactions between Alzheimer's disease and cerebral ischemia-focus on inflammation. Brain Res Brain Res Rev 48 (2005) 240-250
8. Wyss-Coray T., Lin C., Yan F., Yu G.Q., Rohde M., McConlogue L., Masliah E., and Mucke L. TGF-1 promotes microglia amyloid- clearance and reduces plaque burden in transgenic mice. Nature Med 7 (2001) 612-618
9. Katsuse O., Iseki E., and Kosaka K. Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies. Neuropathology 23 (2003) 9-15
10. Schmidt R., Schmidt H., Curb J.D., Masaki K., White L.R., and Launer L.J. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 52 (2002) 168-174
11. Diwan A., Tran T., Misra A., and Mann D.L. Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med 3 (2003) 161-182
12. Agnoletti L., Curello S., Bachetti T., Malacarne F., Gaia G., Comini L., Volterrani M., Bonetti P., Parrinello G., Cadei M., et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-α. Circulation 100 (1999) 1983-1991
13. Oral H., Sivasubramanian N., Dyke D.B., Mehta R.H., Grossman P.M., Briesmiester K., Fay W.P., Pagani F.D., Bolling S.F., Mann D.L., and Starling M.R. Myocardial proinflammatory cytokine expression and left ventricular remodeling in patients with chronic mitral regurgitation. Circulation 107 (2003) 831-837
14. Friedman S.L. Cytokines in liver injury and repair. Sem Liver Dis 19 (1999) 129-140
15. Malemud C.J., Islam N., and Haqqi T.M. Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. Cells Tissues Organs 174 (2003) 34-48
16. Hasel C., Durr S., Rau B., Strater J., Schmid R.M., Walczak H., Bachem M.G., and Moller P. In chronic pancreatitis, widespread emergence of TRAIL receptors in epithelia coincides with neoexpression of TRAIL by pancreatic stellate cells of early fibrotic areas. Lab Invest 83 (2003) 825-836
17. Libby P., Friedman G.B., and Salomon R.N. Cytokines as modulators of cell proliferation in fibrotic diseases. Am Rev Respir Dis 140 (1989) 1114-1117
18. Romagnani P. From basic science to clinical practice: use of cytokines and chemokines as therapeutic targets in renal diseases. J Nephrol 18 (2005) 229-233
19. Crespo J., Rivero M., Fabrega E., Cayon A., Amado J.A., Garcia-Unzeta M.T., and Pons-Romero F. Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci 47 (2002) 1604-1610
20. Kimbrell D.A., and Beutler B. The evolution and genetics of innate immunity. Nature Rev Genet 2 (2001) 256-267
21. Rosenson R.S. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs 1 (2001) 411-420
22. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., and Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78-84
23. Vollmer T., Key L., Durkalski V., Tyor W., Corboy J., Markovic-Plese S., Preiningerova J., Rizzo M., and Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 (2004) 1607-1608
24. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
25. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault R., Wolfson C., and McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59 (2002) 223-227
26. Hajjar I., Schumpert J., Hirth V., Wieland D., and Eleazer G.P. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 57 (2002) M414-M418
27. Rodriguez E.G., Dodge H.H., Birzescu M.A., Stoehr G.P., and Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc 50 (2002) 1852-1856
28. Yaffe K., Barrett-Connor E., Lin F., and Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59 (2002) 378-384
29. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57 (2000) 1439-1443
30. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
31. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
32. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., Wasser D., Johnson-Traver S., Lochhead J., and Ziolwolski C. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62 (2005) 753-757
33. Kivipelto M., Solomon A., and Winblad B. Statin therapy in Alzheimer's disease. Lancet Neurol 4 (2005) 521-522
34. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91 (2002) 988-998
35. Horwich T.B., MacLellan W.R., and Fonarow G.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43 (2004) 642-648
36. Sola S., Mir M.Q., Lerakis S., Tandon N., and Khan B.V. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47 (2006) 332-337
37. Kjekshus J., Dunselman P., Blideskog M., Eskilson C., Hjalmarson A., McMurray J.V., Waagstein F., Wedel H., Wessman P., Wikstrand J., and CORONA Study Group. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 7 (2005) 1059-1069
38. Usui H., Shikata K., Matsuda M., Okada S., Ogawa D., Yamashita T., Hida K., Satoh M., Wada J., and Makino H. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 18 (2003) 265-272
39. Park J.K., Muller D.N., Mervaala E.M., Dechend R., Fiebeler A., Schmidt F., Bieringer M., Schafer O., Lindschau C., Schneider W., et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 58 (2000) 1420-1430
40. Tonelli M., Isles C., Craven T., Tonkin A., Pfeffer M.A., Shepherd J., Sacks F.M., Furberg C., Cobbe M., Simes J., et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112 (2005) 171-178
41. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
42. Bianchi S., Bigazzi R., Caiazza A., and Campese V.M. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41 (2003) 565-570
43. Casey P. Protein lipidation in cell signaling. Science 268 (1995) 221-225
44. Kusama T., Mukai M., Iwasaki T., Tatsuta M., Matsumoto Y., Akedo H., Inoue M., and Nakamura H. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122 (2002) 308-317
45. Poynter J.N., Gruber S.B., Higgins P.D., Almog R., Bonner J.D., Rennert H.S., Low M., Greenson J.K., and Rennert G. Statins and the risk of colorectal cancer. N Engl J Med 352 (2005) 2184-2192
46. Wood S. Prior statin use halves risk of various cancers. Available at: http://www.theheart.org. Accessed June 15, 2006.
47. Jacobs E.J., Rodriguez C., Brady K.A., Connell C.J., Thun M.J., and Calle E.E. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 98 (2006) 4-5
48. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., and White C.M. Statins and cancer risk: a meta-analysis. JAMA 295 (2006) 74-80
49. Yamamoto T., Noble N.A., Cohen A.H., Nast C.C., Hishida A., Gold L.I., and Border W.A. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 49 (1996) 461-469
50. Calabrese F., Valente M., Giacometti C., Pettenazzo E., Benvegnu L., Alberti A., Gatta A., and Pontisso P. Parenchymal transforming growth factor beta-1: its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology. J Gastroenterol Hepatol 18 (2003) 1302-1308
51. Cao B., Guo Z., Zhu Y., and Xu W. The potential role of PDGF, IGF-1, TGF-β expression in idiopathic pulmonary fibrosis. Chin Med J 113 (2000) 776-782
52. Satoh M., Nakamura M., Saitoh H., Satoh H., Maesawa C., Segawa I., Tashiro A., and Hiramori K. Tumor necrosis factor-converting enzyme and tumor necrosis factor-alpha in human dilated cardiomyopathy. Circulation 99 (1999) 3260-3265
53. Tarkowski E., Liljeroth A., Minthon L., Tarkowski A., Wallin A., and Blennow K. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull 61 (2003) 255-260
54. Fox E.J. Immunopathology of multiple sclerosis. Neurology 63 (2004) S3-S7
55. Kiyici M., Gulten M., Gurel S., Nak S.G., Dolar E., Savci G., Adim S.B., Yerci O., and Memik F. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 17 (2003) 713-771
56. Weis M., Pehlivanli S., Meiser B.M., and von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 38 (2001) 814-818
57. Klein B.E.K., Klein R., Lee K.E., and Grady L.M. Statin use and incident nuclear cataract. JAMA 295 (2006) 2752-2758
58. Cushenberry L.M., and de Bittner M.R. Potential use of HMG-CoA reductase inhibitors for osteoporosis. Ann Pharmacother 36 (2002) 671-678